Clinical Report: Insights from the 2025 ASCO Annual Meeting

Overview

Dr. Victoria Villaflor highlights key findings from the 2025 ASCO Annual Meeting, particularly the NIVOPOSTOP trial, which showed a 10% improvement in recurrence-free survival with nivolumab added to standard chemoradiotherapy for high-risk head and neck cancer patients. These findings may lead to significant changes in treatment protocols.

Background

The 2025 ASCO Annual Meeting showcased advancements in cancer treatment, particularly in head and neck oncology. The integration of immunotherapy into postoperative care represents a potential shift in standard practices for managing high-risk patients. Understanding these developments is crucial for improving patient outcomes in oncology.

Data Highlights

Key Findings

• The NIVOPOSTOP trial demonstrated a 10% improvement in recurrence-free survival with nivolumab in high-risk head and neck cancer patients.
• Adjuvant nivolumab combined with standard chemoradiotherapy showed improved locoregional control.
• Grade 4 adverse events increased but remained manageable.
• Other trials, such as KEYNOTE 689, also indicated promising results for perioperative immunotherapy.
• FDA approved pembrolizumab as a perioperative regimen for PD-L1-positive locally advanced head and neck squamous cell carcinoma.

Clinical Implications

Discuss practical steps for clinicians to incorporate findings into treatment plans.

Conclusion

Highlight specific areas for future research and their potential impact on treatment.

References

1. FDA, FDA, 2025 -- FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma
2. The ASCO Post, The ASCO Post, 2025 -- Adding Nivolumab to Adjuvant Chemoradiotherapy Reduces Risk of Recurrence in Patients With Head and Neck Cancer
3. The ASCO Post, The ASCO Post, 2025 -- Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer
4. uci health — Reimagining precision oncology: Richard Van Etten, MD, PhD shares ASCO 2025 insights
5. the asco post — Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice
6. The ASCO Post — 2019 Presidential Address: Caring for Every Patient, Learning From Every Patient
7. roswell park comprehensive cancer center — Roswell Park Quick Talks: Breast Cancer and ADCs, Risk of Second HPV-Related Cancer, Cognitive Function and ICIs
8. Reimagining precision oncology: Richard Van Etten, MD, PhD shares ASCO 2025 insights
9. Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice
10. FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma | FDA
11. Adding Nivolumab to Adjuvant Chemoradiotherapy Reduces Risk of Recurrence in Patients With Head and Neck Cancer - The ASCO Post
12. Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer - The ASCO Post